NCT06220903

Brief Summary

The aim of this study is to investigate objectively the effect of lymphatic fluid which is circulated with Complex Decongestive Therapy on fluid excretion from the body in patients with lymphedema.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

January 15, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 24, 2024

Completed
Last Updated

January 25, 2024

Status Verified

January 1, 2024

Enrollment Period

10 months

First QC Date

January 15, 2024

Last Update Submit

January 24, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • MoistureMeterD Compact Device

    Tissue dielectric constant technique provides information about the emergence of lymphedema in the early stages and the change in the amount of water under the skin. A high-frequency electromagnetic wave produced by the device is directed to the skin by contacting the probe with the skin. The effective measurement depth is 2.5 mm. The device evaluates the amount of water under the tissue thought to be the beginning of lymphedema.

    4 weeks

  • Liquid Intake-Urine Excretion Tracking

    The subjects were asked to fill out a 24-hour fluid intake-urine excretion chart to evaluate the difference between fluid intake and urine excretion.

    4 weeks

Secondary Outcomes (4)

  • Body Mass Index

    4 weeks

  • Range of motion

    4 weeks

  • Evaluation of edema

    4 weeks

  • Lymphedema Quality of Life

    4 weeks

Study Arms (1)

Treatment Group

EXPERIMENTAL

Complex DecongestivePhysiotherapy program was planned for the affected extremity of the cases. The treatment was performed 5 days a week, for 4 weeks, for a total of 20 sessions and each session was 60 minutes. The treatment included Manual Lymph Drainage, skin care, multi-layer bandaging, exercise and compression stockings.

Other: Complex Decongestive Therapy

Interventions

1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied. 2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging. 3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner. 4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught. 5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity.

Treatment Group

Eligibility Criteria

Age30 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female cases
  • Cases diagnosed with lower extremity unilateral/bilateral lymphedema
  • Having received or not received radiotherapy and/or chemotherapy

You may not qualify if:

  • Having received treatment for lymphedema in the last year
  • Having metastatic disease
  • Those diagnosed with severe heart failure and/or arrhythmia
  • Arterial disorders
  • Kidney diseases
  • Infection in affected extremities
  • Psychological disorders
  • Diabetes
  • Nephrotic syndrome
  • Diuretic use
  • Patients using chemotherapy and drugs that have toxic effects on the kidneys
  • Those with liver cirrhosis, liver disease
  • Neurological diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Medipol University

Istanbul, Beykoz, 34100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

LymphedemaEdema

Condition Hierarchy (Ancestors)

Lymphatic DiseasesHemic and Lymphatic DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Cemile Uydur, MsC

    Avrupa Şafak Hospital Physical Therapy and Rehabilitation Unit

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: A study group that received treatment and was monitored for a total of 20 sessions every day.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 15, 2024

First Posted

January 24, 2024

Study Start

September 1, 2018

Primary Completion

June 30, 2019

Study Completion

June 30, 2019

Last Updated

January 25, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations